<DOC>
	<DOCNO>NCT01857479</DOCNO>
	<brief_summary>Inhaled amphotericin , antifungal drug would decrease Aspergillus colonization decrease occurrence exacerbation Allergic Bronchopulmonary Aspergillosis ( ABPA ) .</brief_summary>
	<brief_title>A Randomized Controlled Trial Inhaled Amphotericin B Maintaining Remission Allergic Bronchopulmonary Aspergillosis</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Aspergillosis , Allergic Bronchopulmonary</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B , deoxycholate drug combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>ABPA remission define follow : 1 . Age 1265 year 2 . Diagnosis ABPA Chest Clinic 3 . Received glucocorticoids management ABPA accord Chest clinic protocol ( 0.5 mg/kg/day 4 week , 0.25 mg/kg/day 4 week , 0.125 mg/kg/day 4 week , subsequently taper stop steroid next 4 week ) . 4 . Clinicoradiologic improvement decline IgE level . The chest radiograph IgE level four month steroid therapy would serve baseline 1 . Failure provide inform consent 2 . Pregnancy 3 . Involved research protocol</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ABPA</keyword>
</DOC>